Related Experiment Video
Updated: Jan 15, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Resistant Blood Pressure: New Frontiers in Interventional Hypertension Therapy
Jeffrey D Taylor1, Chukwunonyelum Uche2, Vanessa Rowe2
1Department of Cardiology, University of Illinois Chicago, Chicago, IL, USA. jtaylo68@uic.edu.
Insights
Interventional therapies targeting sympathetic overactivity offer new hope for managing difficult hypertension. Renal denervation shows promise, but secondary causes must be ruled out first.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Neurology
Background:
- Hypertension affects over 1.3 billion globally, a major cause of cardiovascular disease.
- Sympathetic overactivity and autonomic dysregulation are key in hypertension development.
- Interventional device-based therapies are emerging for hypertension management.
Purpose of the Study:
- To review evolving interventional device-based therapies for hypertension.
- To highlight the role of these therapies in resistant hypertension (RH).
- To emphasize the importance of managing secondary hypertension causes.
Main Methods:
- Overview of current interventional approaches: renal denervation (RDN), baroreceptor activation therapy (BAT), carotid body modulation, hepatic denervation, cardiac neuromodulation.
- Review of clinical trial evidence for these therapies.
- Discussion on the necessity of diagnosing secondary hypertension.
Main Results:
- RDN has the most substantial clinical trial evidence among interventional therapies.
- Other neuromodulatory strategies are in early-phase studies.
- Systematic identification and management of secondary hypertension are crucial before interventions.
Conclusions:
- Interventional therapies show potential as adjuncts for hypertension management, particularly RH.
- RDN is the most established interventional therapy currently.
- Future precision-based hypertension management may incorporate these advanced therapies.
Abstract:
Hypertension remains a leading global health challenge, affecting over 1.3 billion individuals worldwide and contributing significantly to cardiovascular morbidity and mortality. In recent years, interventional device-based therapies have emerged as promising adjuncts by targeting sympathetic overactivity and autonomic dysregulation, key mechanisms in the pathogenesis of hypertension. Currently, the use of these interventional therapies is primarily reserved for patients with resistant hypertension (RH) who remain uncontrolled despite optimal medical therapy. This review provides an overview of the evolving landscape of interventional approaches, including renal denervation (RDN), baroreceptor activation therapy (BAT), carotid body modulation, hepatic denervation, and cardiac neuromodulation. Among these, RDN has the most robust clinical trial evidence, while other neuromodulatory strategies are being evaluated in early-phase studies. Additionally, this review underscores the importance of systematically identifying and managing secondary causes of hypertension, such as primary aldosteronism, renovascular disease, and obstructive sleep apnea, before considering procedural interventions. As the field advances, these therapies may assume a more prominent role in precision-based hypertension management.
More Related Videos
04:37Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
08:08Two-photon Imaging of Intracellular Ca2+ Handling and Nitric Oxide Production in Endothelial and Smooth Muscle Cells of an Isolated Rat Aorta
Published on: June 10, 2015
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension II: Pathophysiology
Hypertension and Regulation of Blood Pressure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension V: Nursing Management